NeoGenomics, Inc.

How big is NeoGenomics, Inc.?

As of Jun 18, NeoGenomics, Inc. has a market capitalization of 899.57 million, with net sales of 672.35 million and a net profit of -77.58 million over the latest four quarters. Shareholder's funds are at 902.34 million, and total assets amount to 1,638.04 million.

As of Jun 18, NeoGenomics, Inc. has a market capitalization of 899.57 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 672.35 million, while the sum of net profit for the same period is -77.58 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 902.34 million and total assets at 1,638.04 million.

What does NeoGenomics, Inc. do?

NeoGenomics, Inc. operates cancer-focused genetic testing laboratories and reported net sales of $168 million with a net loss of $26 million as of March 2025. The company has a market cap of $899.57 million and a debt-to-equity ratio of 0.21.

Overview: <BR>NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories in the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 168 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -26 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 899.57 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.21 <BR>Return on Equity: -7.07% <BR>Price to Book: 1.01<BR><BR>Contact Details: <BR>Address: 12701 Commonwealth Dr Ste 9, FORT MYERS FL: 33913-8626 <BR>Tel: ['1 941 9231949', '1 239 6904239'] <BR>Fax: 1 775 3290852 <BR>Website: https://neogenomics.com/

Should I buy, sell or hold NeoGenomics, Inc.?

Who are in the management team of NeoGenomics, Inc.?

As of March 2022, the management team of NeoGenomics, Inc. includes Chairman and CEO Douglas VanOort, Lead Independent Director Lynn Tetrault, Directors Steven Jones and Rachel Stahler, and Independent Directors Bruce Crowther and Alison Hannah. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of NeoGenomics, Inc. includes the following individuals:<BR><BR>- Mr. Douglas VanOort, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mrs. Lynn Tetrault, who is the Lead Independent Director.<BR>- Mr. Steven Jones, who is a Director.<BR>- Ms. Rachel Stahler, who is also a Director.<BR>- Mr. Bruce Crowther, who serves as an Independent Director.<BR>- Dr. Alison Hannah, who is another Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Is NeoGenomics, Inc. overvalued or undervalued?

As of February 25, 2022, NeoGenomics, Inc. is considered overvalued and risky due to negative valuation ratios and significant underperformance compared to the S&P 500.

As of 25 February 2022, the valuation grade for NeoGenomics, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of 1.07, an EV to EBIT of -14.14, and an EV to EBITDA of -131.00. Comparatively, peers such as The Ensign Group, Inc. have a P/E ratio of 32.46 and an EV to EBITDA of 21.10, showcasing a stark contrast in valuation metrics.<BR><BR>Additionally, NeoGenomics has underperformed significantly relative to the S&P 500, with a year-to-date return of -47.69% compared to the index's 12.22%. This underperformance, coupled with the company's negative returns over multiple periods, further reinforces the assessment that NeoGenomics is overvalued in its current state.

Is NeoGenomics, Inc. technically bullish or bearish?

As of August 26, 2025, NeoGenomics, Inc. shows a mildly bearish trend, with daily moving averages indicating bearish sentiment, while outperforming the S&P 500 in the short term but underperforming year-to-date.

As of 26 August 2025, the technical trend for NeoGenomics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment, while the weekly MACD and KST show a mildly bullish outlook. However, the monthly indicators remain predominantly bearish. The stock has outperformed the S&P 500 over the past week and month, returning 3.36% and 38.14% respectively, but it has significantly underperformed over longer periods, with a year-to-date return of -47.69% compared to the S&P 500's 12.22%.